Bruker Corporation (NASDAQ: BRKR) is a Healthcare company (Medical - Devices) with a market capitalization of $9.4B. The Maz Rating grades it against the other companies in its sector.
Bruker Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $61.36, Bruker Corporation trades at 2.7x sales and 4.1x book value, with an EV/EBITDA of 89.2. Over the last twelve months it generated about $3.5B of revenue and a net loss of $168M. It runs a gross margin of 47.9%, an operating margin of 0.0% and a net margin of -3.5%. It shows return on equity of -5.1%, return on invested capital of 0.0% and a free cash flow yield of 2.6%. On the balance sheet: a debt-to-equity ratio of 0.75 and a current ratio of 1.84. Over the past 52 weeks the share price ranged from $32.37 to $68.98, with a beta of 1.26.
Bruker Corporation pays a dividend yielding 0.33%. Its Maz Dividend Score is 1.03 out of 5, ranked against the other dividend payers in its sector (Safety 2.50, Growth 2.10, Yield 1.17, Consistency 1.92).
33 Wall Street analyst ratings cover the stock: 16 Buy, 15 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Bruker Corporation (BRKR) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 19.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 1.85% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 19.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.85% / 33% · Receivables / Mkt Cap (36m) 7.47% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 19.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.85% / 33.33% · Receivables / Mkt Cap (24m) 7.47% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 29.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.23% / 33.33% · Receivables / Avg Assets (4Q) 12.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 29.4% / 33.33% · (Cash+ST Inv) / Total Assets 2.87% / 33.33% · (Cash+Recv) / Total Assets 14.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Bruker Corporation (BRKR) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Bruker Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Bruker Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.